Xiaomei Ma, PhD
Cards
Titles
Co-Leader, Cancer Prevention and Control
Contact Info
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
About
Titles
Interim Department Chair and Professor of Epidemiology (Chronic Diseases)
Co-Leader, Cancer Prevention and ControlBiography
Dr. Ma is Professor of Epidemiology at the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She studies the etiology and health outcomes of different types of cancer, with a focus on pediatric cancer and malignancies of the hematopoietic system (e.g., leukemia, lymphoma, myelodysplastic syndromes, and myeloproliferative neoplasms). Her research has addressed the impact of immunological factors, chemical exposures, and genetic characteristics on the risk of cancer. In addition, she has assessed the patterns of care and cost implications of cancer screening and treatment in older adults.
Appointments
Chronic Disease Epidemiology
ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- Climate Change and Health
- COPPER Center
- K12 Calabresi Immuno-Oncology Training Program (IOTP)
- Yale Cancer Center
- Yale School of Public Health
- Yale Ventures
Education & Training
- PhD
- University of California at Berkeley (2001)
Research
Overview
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Rong Wang, PhD
Amer Zeidan, MBBS
Nikolai Podoltsev, MD, PhD
Scott Huntington, MD, MPH, MSc
Cary Gross, MD
Michael S. Leapman, MD, MHS
Myelodysplastic Syndromes
Neoplasms
Leukemia
Myeloproliferative Disorders
Chronic Disease
Lymphoma
Publications
High ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study
Rogne T, Wang R, Wang P, Deziel N, Metayer C, Wiemels J, Chen K, Warren J, Ma X. High ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study. The Lancet Planetary Health 2024, 8: e506-e514. PMID: 38969477, DOI: 10.1016/s2542-5196(24)00121-9.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsRisk of childhood acute lymphoblastic leukemiaChildhood acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaLatino childrenNon-Latino white childrenAssociated with risk of adverse pregnancy outcomesCalifornia Cancer RegistryRisk of acute lymphoblastic leukemiaCalifornia birth recordsRisk of adverse pregnancy outcomesPre-pregnancy periodAssociated with riskBayesian meta-regressionNational Institutes of HealthCancer RegistryCases of childhood acute lymphoblastic leukemiaNational Center for Advancing Translational SciencesAdverse pregnancy outcomesAcute lymphoblastic leukemia casesInstitutes of HealthInvestigation of mechanistic pathwaysBirth recordsGestational weeks 8Pre-pregnancyFolate metabolism and risk of childhood acute lymphoblastic leukemia: a genetic pathway analysis from the Childhood Cancer and Leukemia International Consortium
Metayer C, Spector L, Scheurer M, Jeon S, Scott R, Takagi M, Clavel J, Manabe A, Ma X, Hailu E, Lupo P, Urayama K, Bonaventure A, Kato M, Meirhaeghe A, Chiang C, Morimoto L, Wiemels J. Folate metabolism and risk of childhood acute lymphoblastic leukemia: a genetic pathway analysis from the Childhood Cancer and Leukemia International Consortium. Cancer Epidemiology Biomarkers & Prevention 2024, of1-of5. PMID: 38904462, DOI: 10.1158/1055-9965.epi-24-0189.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsGenome-wide dataAncestry groupsFolate metabolic pathwayGenetic variantsChildhood cancerMetabolic pathwaysGenetic pathway analysisRisk of childhood ALLRisk of childhood acute lymphoblastic leukemiaGene-folate interactionsChildhood ALL riskCase-control studyDNA methylationMETAL softwareGenetic studiesNucleotide polymorphismsPathway analysisMeta-analysis of original dataALL riskGenetic effectsAncestryFolate pathwayMaternal genetic effectsFolate intakePD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchConceptsMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original Research‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.Peer-Reviewed Original ResearchAltmetricConceptsProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerActive surveillanceActive surveillance of prostate cancerGleason Grade Group 1Surveillance of prostate cancerIntermediate-risk prostate cancerMonitoring of prostate cancerMRI-ultrasound fusion biopsyGrade group 1Monitoring prostate cancerGroup 2 tumorsMagnetic resonance imaging scansFusion biopsyLongitudinal follow-upProstate biopsyFollow-upProstateSemi-structured interviews of patientsMRI useQualitative studyGroup 1Interviews of patientsPatientsA noncoding regulatory variant in IKZF1 increases acute lymphoblastic leukemia risk in Hispanic/Latino children
de Smith A, Wahlster L, Jeon S, Kachuri L, Black S, Langie J, Cato L, Nakatsuka N, Chan T, Xia G, Mazumder S, Yang W, Gazal S, Eng C, Hu D, Burchard E, Ziv E, Metayer C, Mancuso N, Yang J, Ma X, Wiemels J, Yu F, Chiang C, Sankaran V. A noncoding regulatory variant in IKZF1 increases acute lymphoblastic leukemia risk in Hispanic/Latino children. Cell Genomics 2024, 4: 100526. PMID: 38537633, PMCID: PMC11019360, DOI: 10.1016/j.xgen.2024.100526.Peer-Reviewed Original ResearchAltmetricConceptsHispanic/Latino childrenNon-Hispanic White individualsHigher risk of acute lymphoblastic leukemiaRisk of acute lymphoblastic leukemiaNoncoding regulatory variantsFine-mapping analysisAcute lymphoblastic leukemia riskAcute lymphoblastic leukemiaEvidence of selectionIndigenous American ancestryReduced enhancer activityRisk allele frequenciesIncreased ALL riskRegulatory variantsHispanic/Latino individualsPro-B cellsHispanic/Latino populationRacial/ethnic groupsDownstream enhancerGenetic basisLeukemia riskWhite individualsAllele frequenciesAmerican ancestryALL riskTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchConceptsProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiariesRacial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
Links & Media
News
- July 03, 2024
Ambient heat during pregnancy linked to increased risk of childhood cancer
- May 15, 2024
Leadership Change in Department of Chronic Disease Epidemiology
- January 16, 2024
Cancer epidemiology, attentive faculty brought PhD student to YSPH
- November 15, 2023
YSPH alumna Margaret Mayer embraces challenge of grant management at the National Cancer Institute
Get In Touch
Contacts
Chronic Disease Epidemiology
PO Box 208034, 60 College Street
New Haven, CT 06520-8034
United States
Locations
60 College Street
Academic Office
Ste 406
New Haven, CT 06510